Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<IPO> Maiwei Biotech (02493.HK) Oversubscribed 480.71x; 70,000 Shares Subscription Secures One Board Lot
Recommend 6 Positive 7 Negative 4 |
||||
|
||||
|
Maiwei Biotech-B (02493.HK) announced its IPO results. The Hong Kong public offering was oversubscribed by 481.71 times. The allotment rate for one board lot (200 shares) was 1%, and a subscription of 70,000 shares guarantees one board lot. The international offering was oversubscribed by 3.46 times. The final offer price was set at HKD27.64, the bottom of the indicative range, with net proceeds of HKD1.189 billion. The shares are expected to be listed on Tuesday (28th). Chinese pharmaceutical company Maiwei Biotech plans to globally offer 47.1302 million shares, with the public offering accounting for 10%. The offer price ranged from HKD27.64 to HKD30.71. Six cornerstone investors, including Junshi Hong Kong, Sanjin International, Guohui Hong Kong, Changrong International, WuXi Biologics Venture and Zhonghe Capital, collectively subscribed for 15.0206 million shares, representing 31.87% of the total offering. The last day of the lock-up undertaking is October 27, 2026. (de/d) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
